B.ThomsenH
Lilly ha anunciado los resultados detallados de tres ensayos clnicos Fase III del programa ACHIEVE que evalan el uso de orforglipron, el GLP-1 oral que se toma sin restricciones de alimentos ni agua, en adultos con diabetes tipo 2
Its the reason the FDA has been hesitant to approve GLP-1 use for people with type 1 diabetes, says Dace Trence, MD, the president of American Association of Clinical Endocrinology and a professor emeritus at the University of Washington in Seattle
Human Evidence Human research primarily involves topical application
Comorbidities collected within 6 months before the index date included metabolic syndrome (hypertension and dyslipidemia), cardiovascular disorders (heart failure, myocardial infarction, ischemic stroke, peripheral arterial disease, coronary artery disease, cardiovascular disease [CVD]), and chronic kidney disease
Those with dull, dry, or uneven skin lacking moisture